Aktienanalyse zu Tyra Biosciences Inc (TYRA)TYRATyra Biosciences Inc

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tyra Biosciences Inc is currently priced at $20.45, which is significantly below the average analyst price target of $39.75. However, the company is facing ongoing losses, with a projected EPS of -0.66 for the next earnings report and a negative net income trend, which raises concerns about its profitability. Additionally, insider selling has increased by 100.98% over the last month, indicating potential lack of confidence from insiders. Given these factors, it may be prudent to hold off on buying until there are clearer signs of financial improvement or positive catalysts.